Sorafenib-Related Adverse Events in Predicting the Early Radiologic Responses of Hepatocellular Carcinoma

Gastroenterology Research
doi 10.14740/gr1109
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elmer Press, Inc.

Related search

Efficacy and Adverse Events of Transcatheter Arterial Chemoembolization in Combination With Sorafenib in the Treatment of Unresectable Hepatocellular Carcinoma

Molecular and Clinical Oncology
Cancer ResearchOncology
2015English

Predicting Survival in Early Hepatocellular Carcinoma

Gut
Gastroenterology
2005English

Sorafenib in Hepatocellular Carcinoma

Clinical Medicine. Therapeutics
2009English

mRECIST Response Combined With Sorafenib-Related Adverse Events Is Superior to Either Criterion Alone in Predicting Survival in HCC Patients Treated With TACE Plus Sorafenib

International Journal of Cancer
Cancer ResearchOncology
2016English

Letter: Are Sorafenib-Related Adverse Events Associated With Prolonged Survival? Authors' Reply

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2019English

Cytotoxicity of Sorafenib in Human Hepatocellular Carcinoma Cells

Al-Azhar Journal of Pharmaceutical Sciences
2015English

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2008English

Factors Predicting Early Recurrence After Surgical Resection of Hepatocellular Carcinoma

Journal of Hepatology
Hepatology
2019English

Sorafenib vs Nivolumab in Patients With Hepatocellular Carcinoma

Journal of Liver Research, Disorders & Therapy
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy